"I am excited to be working with Asterias' talented employees, whose hard work and incredible talent have been responsible for the rapid advancement of a number of promising treatments," said Mr. Lichtinger. "The pluripotent stem cell technology platform is rapidly emerging into the clinic with a focus on major unmet medical needs that have limited or no cures available. Asterias' two most advanced clinical programs have the pot
Big pharma to partner with our cancer ip, will eventually rival Pfizer and their recent t-cell partnership. Question is who will be Biotimes partner? J&J, TEVA, Merck?
9 MIL cash, 2 MIL debt, a ECM scaffold but no stem cells and hasn't even started trials....my money is with BTX.
The Scientist » News & Opinion » Daily News
SCNT Picks Up Steam
Study confirms that somatic cell nuclear transfer, an alternate method of creating patient-specific pluripotent stem cells, can be used to reprogram adult cells.
Scientists at the New York Stem Cell Foundation (NYSCF) Research Institute, along with their international colleagues, have produced human embryonic stem cells (hESCs) by transferring the nuclei of skin cells from a 32-year-old type 1 diabetic woman into human eggs whose own nuclei had been removed, according to a study published today (April 28) in Nature. The researchers induced the hESCs to differentiate into insulin-secreting cells. They hope to eventually replace cells that type 1 diabetes patients lack with patient-specific insulin-secreting cells.
The publication comes hot on the heels of a study published earlier this month (April 17) in Cell Stem Cell that also showed the technique, called somatic cell nuclear transfer (SCNT), could be used on adult cells.
“This is the first report describing diploid patient-specific stem cell lines after somatic cell nuclear transfer, and together with the report that appeared . . . in Cell Stem Cell, it is also the first report on the derivation of diploid pluripotent stem cell lines from cells of an adult and from a human being after birth in general,” study coauthor Dieter Egli, a senior research fellow at the NYSCF, said during a press conference.
“This is an important demonstration that SCNT works and can be used to model and perhaps one day treat disease,” George Daley, a stem cell biologist at the Harvard Stem Cell Institute, Children’s Hospital Boston, and the Dana-Farber Cancer Institute, wrote in an e-mail to The Scientist. Daley was not involved in the research.
SCNT is a cellular-reprogramming alternative, and its products could have advantages over induced pluripotent s
BTX also licensing Cornell's vascular stem cell ip, use for this ip will also be combined with our acquired Cell Targeting nano-peptide tumor destroying ip. Announcements of our revolutionary cancer therapy product clinical trials will also take place at many top hospitals including Cornell.
More proof Biotimes extra-cellular matrix is a winner! Very important since our regen devices are all based on HyStem.
No where to go but up!
Two low hanging fruit products:
Cancer diagnostic product Panc-DX and Renevia(adipose cell/ECM derived plastic surgery product). Both products due out on the market within 6 months! BUY-BUY-BUY!
The first of seven subsidiaries will IPO shortly after announcing the the restart of Geron spine trials. Gonna be good!
Our cancer ip rivals that of Merck, and Pfizer!